ArticleCell death & disease2017
Mycobacterium abscessus glycopeptidolipids inhibit macrophage apoptosis and bacterial spreading by targeting mitochondrial cyclophilin D.
Article in Cell death & disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 58 citations in OpenAlex.
- Article
- Article
- Clinical manifestations of Mycobacterium abscessus lung disease according to different morphotypes.Journal of global health · 2026Article
- Punicalagin Enhances Autophagy Through Sirtuin 1/FoxO3a Axis to Inhibit Intracellular Mycobacterium Abscessus Infection.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Functional characterization of GplA (MSMEG-0394) reveals a novel determinant of glycopeptidolipids homeostasis inFrontiers in microbiology · 2026Article
- Comparative analysis of drug susceptibility among different Mycobacterium abscessus morphotypes.BMC microbiology · 2025Article
- Pathogenicity and virulence ofVirulence · 2025Review
- Identification of apoptosis-related genes as potential biomarkers and therapeutic targets in cystic fibrosis patients progressing to pulmonary nontuberculous mycobacterial disease.Scientific reports · 2025Article
- Cell Death Mechanisms inPathogens (Basel, Switzerland) · 2025Review
- Cell envelope polysaccharide modifications alter the surface properties and interactions ofmBio · 2025Article
- The soil Mycobacterium sp. promotes health and longevity through different bacteria-derived molecules in Caenorhabditis elegans.Aging cell · 2025Article
- Differential Immune Responses and Underlying Mechanisms of Metabolic Reprogramming in Smooth and Rough Variants ofPathogens (Basel, Switzerland) · 2023Article
- The synergetic effect of sitafloxacin-arbekacin combination in the Mycobacterium abscessus species.Scientific reports · 2023Article
- Spotlight on mycobacterial lipid exploitation using nanotechnology for diagnosis, vaccines, and treatments.Nanomedicine : nanotechnology, biology, and medicine · 2023Review
- Review
- Comparison of Macrophage Immune Responses and Metabolic Reprogramming in Smooth and Rough Variant Infections ofInternational journal of molecular sciences · 2022Article
- Virulence Mechanisms ofFrontiers in microbiology · 2022Review
- Host-Pathogen Interactions Operative duringImmune network · 2021Review
- The Role of NRF2 in Mycobacterial Infection.Antioxidants (Basel, Switzerland) · 2021Review
- Non-tuberculous mycobacteria immunopathogenesis: Closer than they appear. a prime of innate immunity trade-off and NTM ways into virulence.Scandinavian journal of immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycobacterium abscessus (MAB) is a species of nontuberculous mycobacteria (NTM) and a major causative pathogen of pulmonary diseases especially in patients with cystic fibrosis. MAB infection is notoriously difficult to treat because of its intrinsic or inducible resistance to most antibiotics. The rough (R) morphotype of MAB, lacking cell surface glycopeptidolipids (GPLs), is associated with more severe and persistent infection than the smooth (S) type; however, the mechanisms underlying the R type's virulence and the relation with GPLs remain unclear. In this study, we found that R-type MAB is much more proapoptotic than the S type, as a result of GPL-mediated inhibition of macrophage apoptosis. Polar GPLs inhibited an apoptotic response (induced by proapoptotic stimuli) by suppressing ROS production and the cytochrome c release and by preserving mitochondrial transmembrane potential. Furthermore, GPLs were found to be targeted to mitochondria and interacted with cyclophilin D; their acetylation was essential for this interaction. Finally, GPLs inhibited the intracellular growth and bacterial spreading of R-type MAB among macrophages via apoptosis inhibition. These findings suggest that GPLs limit MAB virulence by inhibiting apoptosis and the spread of bacteria and therefore provide a novel insight into the mechanism underlying virulence of MAB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.